Results 141 to 150 of about 1,511,681 (307)

PRM12 Joint Estimation of Progression Free Survival and Overall Survival [PDF]

Value in Health, 2012
G. Bergman, M.J. Ouwens
openaire   +2 more sources

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer

, 2002
H. Tsuda, Y. Hashiguchi, S. Nakata, M. Deguchi, S. Negoro, O. Ishiko, K. Yamamoto   +6 more
openalex   +1 more source

Mutagen sensitivity predicts poor overall and disease specific survival in patients with stage III non-small cell lung cancer treated with chemo/radiotherapy [PDF]

, 2004
Joshua Chang, Xiao Yu Wu, R. Komaki, Ryouhei Sasaki, Pamela K. Allen, Zhibin Liao, Craig W. Stevens, Chien‐Hsing Lu, Frank V. Fossella, James D. Cox   +9 more
openalex   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

A Short Mutational Hot Spot in the First Intron of BCL-6 Is Associated with Increased BCL-6 Expression and with Longer Overall Survival in Large B-Cell Lymphomas

, 2002
María-Jesús Artiga, Ana-Isabel Sáez, Cristina Romero, Margarita Sánchez‐Beato, Marisol Mateo, Concepción Navas, Manuela Mollejo, Miguel Á. Piris   +7 more
openalex   +1 more source

Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy [PDF]

, 2005
Yair Lotan, Amit Gupta, Shahrokh F. Shariat, Ganesh S. Palapattu, Amnon Vazina, Pierre I. Karakiewicz, Patrick J. Bastian, Craig Rogers, Gilad E. Amiel, Paul Perotte, Mark Schoenberg, Seth P. Lerner, Arthur I. Sagalowsky   +12 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival [PDF]

, 2005
Susanne Schnittger, Tobias Kohl, Torsten Haferlach, Wolfgang Kern, Wolfgang Hiddemann, Karsten Spiekermann, Claudia Schoch   +6 more
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source